|
Today's Headlines
Influenza vaccination reduced children’s risk of pediatric intensive care unit admission for flu by three-fourths during 2010 to 2011 and 2011 to 2012, according to a Centers for Disease Control and Prevention study. » Full article
|
|
FDA has approved Coagulation Factor IX (Recombinant), Fc Fusion Protein (Alprolix, Biogen Idec), for use in adults and children who have hemophilia B; it also granted the product orphan-drug designation. Alprolix is the first hemophilia B treatment designed for less-frequent injections when used to prevent or reduce bleeding frequency. » Full article
|
Continuing Education
This month's article is the second in a new year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease.
From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.
This month, the professional development activity is “MTM essentials for management of CAD and PAD,” a knowledge-based activity worth up to 2 credits.
The goal of this activity is to review therapeutic strategies pharmacists can utilize to improve patient care in the management of coronary artery disease and peripheral artery disease.
To read and print the article with TEST QUESTIONS, click here.
To proceed to the online exams and earn up to 2 CPE credits, click here to log in.
Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide
or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at
www.MyCPEmonitor.net. This profile will enable you to have one login
for all the NABP programs and services you will need throughout your career.
|
|
|
EDITOR'S PICK
With total healthcare costs in the United States approaching $3 trillion, and costs for a wide range of drugs approaching nearly 15% of healthcare costs overall, or $450 billion, the industry is shifting toward a new emphasis focused on drug formularies. » Full article
|
|
Like
Tweet
